23
Participants
Start Date
September 27, 2021
Primary Completion Date
July 12, 2023
Study Completion Date
September 11, 2024
Tarlatamab
Tarlatamab will be administered as an intravenous (IV) infusion.
AMG 404
AMG 404 will be administered as an intravenous (IV) infusion.
Universitaetsklinikum Allgemeines Krankenhaus Wien, Vienna
Universitair Ziekenhuis Antwerpen, Edegem
Universitair Ziekenhuis Leuven - Campus Gasthuisberg, Leuven
Medizinische Universitaet Innsbruck, Innsbruck
Taipei Veterans General Hospital, Taipei
Wake Forest Baptist Comprehensive Cancer Research Center, Winston-Salem
Medical University of South Carolina, Charleston
Tennessee Oncology, PLLC, Nashville
Chung Shan Medical University Hospital, Taichung
University of Kentucky, Lexington
University Hospitals Cleveland Medical Center, Cleveland
Northwestern University, Robert H Lurie Comprehensive Cancer Center, Chicago
Huntsman Cancer Institute, Salt Lake City
National University Hospital, Singapore
National Cancer Centre Singapore, Singapore
National Cancer Center Hospital East, Kashiwa-shi
National Cancer Center Hospital, Chuo-ku
Lead Sponsor
Amgen
INDUSTRY